Abstracts
Résumé
Récemment, plusieurs équipes ont montré l’intérêt potentiel des transferts de gènes, à l’aide de divers vecteurs, dans des modèles animaux de douleurs chroniques. Le transfert de gènes codant pour des précurseurs de peptides opioïdes endogènes, conduisant à la production - dans la moelle épinière ou les neurones sensoriels primaires - de grandes quantités de peptides physiologiquement actifs qui en dérivent, se traduit par une diminution marquée des douleurs chroniques d’origine inflammatoire ou neurologique. D’autres molécules, comme les cytokines, impliquées dans l’induction ou la persistance des douleurs, représentent des cibles potentielles de ces approches. Bien que des progrès importants aient été réalisés dans le développement des vecteurs utilisés, leur innocuité reste à démontrer chez l’homme avant d’envisager la thérapie génique des douleurs chroniques rebelles aux traitements actuellement disponibles.
Summary
Chronic pain is frequently associated with profound alterations of neuronal systems involved in pain processing and should be considered as a real disease state of the nervous system. Unfortunately, some forms of chronic pain remain difficult to be satisfactorily treated. In the search for new therapeutic strategies, the gene-based approaches are of potential interest as they offer the possibility to introduce a therapeutic protein into some relevant structures and to drive its continuous production in the near vicinity of targeted cells. Recently, these techniques have been experimented in several animal models of chronic pain, showing that transfer at the spinal level of some genes, in particular those of opioid precursors proopiomelanocortin or proenkephalin A, leading to the overproduction of products that they encode, attenuated persistent pain of both inflammatory and neuropathic origin. Thus, in polyarthritic rat, a model of chronic inflammatory pain, we demonstrated that herpes simplex virus vector mediated overexpression of proenkephalin A in primary sensory neurons at the lumbar level elicited both antihyperalgesic and anti-inflammatory activities. Apart from opioids, numerous other molecules involved in pain processing are of potential therapeutic interest for gene-based protocols. For instance, targeting some molecules involved in pain induction and perpetuation, such as proinflammatory cytokines, raises an interesting possibility to block the «development» of pain. The clinical application of these approaches remains to be established, and, presently, one of the main problems to be solved is the innocuity of virus-derived vectors. However, the experimental use of gene-based techniques might be particularly useful for the evaluation of the therapeutic interest of some recently identified molecules involved in pain processing and might finally lead to the development of new “classical” pharmacological tools.
Appendices
Références
- 1. Hsich G, Sena-Esteves M, Breakefield XO. Critical issues in gene therapy for neurologic disease. Hum Gene Ther 2002 ; 13 : 579-604.
- 2. Pohl M, Braz J. Gene therapy of pain : emerging strategies and future directions. Eur J Pharmacol 2001 ; 429 : 39-48.
- 3. Wu CL, Garry MG, Zollo RA, Yang J. Gene therapy for the management of pain. Anesthesiology 2001 ; 94 : 1119-32.
- 4. Lin CR, Yang LC, Lee TH, et al. Electroporation-mediated pain-killer gene therapy for mononeuropathic rats. Gene Ther 2002 ; 9 : 1247-53.
- 5. Finegold AA, Mannes AJ, Iadarola MI. A paracrine paradigm for in vivo gene therapy in the central nervous system : treatment of chronic pain. Hum Gene Ther 1999 ; 10 : 1251-7.
- 6. Wilson SP, Yeomans DC, Bender MA, et al. Antihyperalgesic effects of infection with a preproenkephalin-encoding herpes virus. Proc Natl Acad Sci USA 1999 ; 96 : 3211-6.
- 7. Goss JR, Mata M, Goins WF, et al. Antinociceptive effect of a genomic herpes simplex virus-based vector expressing human proenkephalin in rat dorsal root ganglion. Gene Ther 2001 ; 8 : 551-6.
- 8. Hao S, Mata M, Goins W, et al. Transgene mediated enkephalin release enhances the effect of morphine and evades tolerance to produce a sustained antiallodynic effect in neuropathic pain. Pain 2003 ; 102 : 135-42.
- 9. Goss JR, Harley CF, Mata M, et al. Herpes vector-mediated expression of proenkephalin reduces bone cancer pain. Ann Neurol 2002 ; 52 : 662-5.
- 10. Antunes Bras JM, Epstein AE, Bourgoin S, et al. Herpes simplex virus 1-mediated transfer of preproenkephalin A in rat dorsal root ganglia. J Neurochem 1998 ; 70 : 1299-303.
- 11. Braz J, Beaufour C, Coutaux A, et al. Therapeutic efficacy in experimental polyarthritis of viral-driven enkephalin overproduction in sensory neurons. J Neurosci 2001 ; 21 : 7881-8.
- 12. Braz J, Meunier A, Beaufour C, et al. Therapeutic efficacy in experimental polyarthritis of viral-driven enkephalin overproduction in sensory neurons. In : Dostrovsky JO, Carr DB, Kotzenburg M, eds. Proceedings of the 10th World congress on pain. Seattle : IASP Press, 2003 : 960 p.
- 13. Takeba Y, Suzuki N, Kaneko A, et al. Endorphin and enkephalin ameliorate excessive synovial cell functions in patients with rheumatoid arthritis. JRheumatol 2001 ; 28 : 2176-83.
- 14. Oprée A, Kress M. Involvement of the proinflammatory cytokines tumor necrosis factor-α, IL-1β, and IL-6 but not IL-8 in the development of heat hyperalgesia : effects on heat-evoked calcitonin gene-related peptide release from rat skin. J Neurosci 2001 ; 20 : 6289-93.
- 15. Inoue A, Ikoma K, Morioka N, et al. Interleukin-1beta induces substance P release from primary afferent neurons through the cyclooxygenase-2 system. J Neurochem 1999 ; 73 : 2206-13.
- 16. Junker U, Böhnlein E. Gene therapy for arthritis 1996-1999. Exp Opin Ther Patents 1999 ; 9 : 1491-8.
- 17. Watkins LR, Milligan ED, Maier SF. Glial activation : a driving force for pathological pain. Trends Neurosci 2001 ; 24 : 450-5.
- 18. Fernandes JC, Martel-Pelletier J, Pelletier JP. Gene therapy for osteoarthritis. Clin Orthop 2000 ; 379 (suppl) : S262-72.
- 19. Wagner R, Janjigian M, Myers RR. Anti-inflammatory interleukin-10 therapy in CCI neuropathy decreases thermal hyperalgesia, macrophage recruitment, and endoneurial TNF-α expression. Pain 1998 ; 74 : 35-42.
- 20. Cunha FQ, Poole S, Lorenzetti BB, et al. Cytokine-mediated inflammatory hyperalgesia limited by interleukin-4. Br J Pharmacol 1999 ; 126 : 45-50.
- 21. Yao MZ, Gu JF, Wang JH, et al. Interleukin-2 gene therapy of chronic neuropathic pain. Neuroscience 2002 ; 112 : 409-16.
- 22. Milligan ED, O’Connor KA, Hamack SE, et al. A novel gene therapy approach for controlling pathological pain states : intrathecal delivery in rats of viral vectors encoding the anti-inflammatory cytokine, interleukin-10. Proceedings of the 10th World congress on pain. Seattle: IASP Press, 2002; 135 (abstract 392-P26).
- 23. Lu CY, Chou AK, Wu CH, et al. Gene-gun particle with pro-opiomelanocortin cDNA produces analgesia against formalin-induced pain in rats. Gen Ther 2002 ; 9 : 1008-14.
- 24. Eaton MJ, Blits B, Ruitenberg MJ, et al. Amelioration of chronic neuropathic pain after partial nerve injury by adeno-associated viral (AAV) vector-mediated over-expression of BDNF in the rat spinal cord. Gen Ther 2002 ; 9 : 1387-95.